Savana develops AI technologies that unlock clinical value from routinely stored hospital data by extracting insights from the free text of clinical notes and combining them with systems biology information. The platform produces real-world evidence to help target patients, find biomarkers, accelerate drug development, test hypotheses, and repurpose molecules. Its tools generate predictive models and deliver insights to doctors and researchers to optimize R&D and patient care. The company plans to expand its data-analysis capabilities to include new data layers such as genomics, biomolecular data, and images, and to ingest information generated during clinical trials. Savana says its technology has been used by more than 200 hospitals to extract insights from over 2 billion medical records across 16 countries in Western Europe and the Americas. The company has previously raised $15 million in a Series B to expand into America and recently secured an additional $25 million booster round. Savana develops AI-driven SaaS tools that surface critical information from the free text of clinical notes to give doctors, pharmacists and life-science customers actionable patient insights. Its platform has processed more than 400 million electronic medical records in English, Spanish, German and French. The company says health systems across Western Europe, the United States and Canada use its technologies, and it works with the top 20 global pharmaceutical companies and over a hundred healthcare facilities. Savana was founded in 2014 in Spain and is led by CEO Jorge Tello and CMO Dr. Ignacio Hernandez Medrano; the team comprises more than 100 professionals. The company plans to use fresh funding to support international expansion and to grow operations in the U.S., including headcount at its New York City headquarters.

Total raised

$40M

Funding rounds

2

Latest round

Equity

Latest activity

Apr 2022